Budesonide for the Treatment of Inflammatory Bowel Disease
نویسندگان
چکیده
منابع مشابه
Application of extracellular vesicles in the treatment of inflammatory bowel disease
Introduction: Inflammatory bowel disease(IBD) is caused by genetic, environmental, microbial and immune factors. IBD has two primary forms: Ulcerative colitis and Crohn´s disease. The incidence of IBD has significantly increased over the last few decades. Given that patients have poor response to drug treatments or are resistant to drug therapies, new therapies are needed for gastrointestinal i...
متن کاملNeonatal Presentation of Unremitting Inflammatory Bowel Disease
Very-early-onset inflammatory bowel disease (VEO-IBD) has a distinct phenotype and should be considered a specific entity. VEO-IBD presents with very severe clinical pictures and is frequently known by an indeterminate colitis whose clinical remission is unmanageable. This study examines the case of a neonate with VEO-IBD, not responding to medical and surgical treatment. A 7-day-old Iranian fe...
متن کاملan overview on inflammatory bowel disease treatment
inflammatory bowel disease (ibd) is a chronic relapsing, idiopathic disorder of the gastrointestinal tract of an unknown etiology. ulcerative colitis (uc) and crohn's disease (cd) have become important health problems.â current medical therapy of ibd has advanced dramatically with the introduction of new biologic therapies in addition to the optimization of conventional therapies that include ...
متن کاملSmall therapeutic molecules for the treatment of inflammatory bowel disease.
New therapies for inflammatory bowel disease are needed, because standard therapies fail to induce remission in about 30% of patients, and because of the relative inefficacy of current maintenance therapies. This review summarises the current status of the development of small therapeutic molecules for inflammatory bowel disease.
متن کاملVedolizumab for the treatment of inflammatory bowel disease.
The causes of inflammatory bowel diseases, such as ulcerative colitis (UC) and Crohn's disease (CD), remain to be elucidated. However, characteristic inflammation of the gastrointestinal mucosa is caused by infiltration of T lymphocytes into the submucosal layer. Inhibiting this immune response is a promising therapeutic target. Integrins expressed on the cell surface mediate gut homing of T ly...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Journal of Gastroenterology
سال: 1994
ISSN: 0835-7900
DOI: 10.1155/1994/956865